| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
S&P Global Ratings Update
|
16 Sep 2024 8:52AM |
$5.010 |
$5.100 |
risen by
1.80%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Outcome of Constitutional Review of New French Tax
|
13 Sep 2024 8:32AM |
$4.910 |
$5.100 |
risen by
3.87%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Change of Director's Interest Notice - Graeme Bevans
|
9 Sep 2024 2:59PM |
$4.855 |
$5.100 |
risen by
5.05%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
SCC Rate Case Outcome for Dulles Greenway
|
5 Sep 2024 8:26AM |
$5.070 |
$5.100 |
risen by
0.59%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- The Commonwealth of Virginia State Corporation Commission (SCC) denied TRIP II’s application for toll increases at the Dulles Greenway.
- TRIP II sought a 39.7% increase for the maximum peak toll and a 21.9% increase for the maximum off-peak toll.
- Atlas Arteria is reviewing the SCC Final Order and considering all available options.
- The Final Order is accessible on the SCC website and also on Atlas Arteria’s website.
- Atlas Arteria owns a 100% economic interest in the Dulles Greenway, a 22km toll road in Virginia.
- Atlas Arteria Group consists of multiple toll road interests including APRR and ADELAC in France, Chicago Skyway in the US, and Warnow Tunnel in Germany.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Change of Director's Interest Notice - Ken Daley
|
3 Sep 2024 3:04PM |
$5.145 |
$5.100 |
fallen by
0.87%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Investor Reference Pack to 30 June 2024
|
29 Aug 2024 8:21AM |
$5.090 |
$5.100 |
risen by
0.20%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria trades on the Australian Securities Exchange as a stapled security under the code 'ALX'.
- Atlas Arteria's business portfolio includes interests in APRR, ADELAC, Dulles Greenway, Warnow Tunnel, and Chicago Skyway.
- The company provided a detailed analysis of traffic, revenue, and EBITDA for its assets.
- As of 30 June 2024, Atlas Arteria's economic interest in APRR and ADELAC changed to 30.82% and 30.85% respectively following a capital increase at MAF2.
- Atlas Arteria reported on financing and debt metrics for its various assets.
- The report includes maps and detailed descriptions of each toll road asset.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Half Year Results Investor Presentation to 30 June 2024
|
29 Aug 2024 8:20AM |
$5.090 |
$5.100 |
risen by
0.20%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria reported their half-year results for the period ending 30 June 2024.
- The company saw a 3.8% increase in toll revenue and a 0.4% increase in traffic.
- Total EBITDA decreased by 2.9%, primarily due to the new French tax (TEILD).
- The company maintained its distribution guidance for 2024 at 40 cents per security.
- Hugh Wehby was appointed as the incoming CEO and Managing Director, starting late 2024.
- Atlas Arteria achieved significant progress on sustainability targets, including a reduction in Scope 1 and 2 emissions.
- Key financial highlights include a proportionate toll revenue increase of 3.8% and total revenue increase of 4.8%.
- The company has implemented a new reporting methodology for centralized costs starting from H1 2024.
- Capital management initiatives include a €200 million cash reserve release to fund debt amortization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Half Year Results Announcement to 30 June 2024
|
29 Aug 2024 8:16AM |
$5.090 |
$5.100 |
risen by
0.20%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- 2024 distribution guidance of 40.0 cents per security reaffirmed
- Strong growth in proportionate toll revenue (+3.8% compared to H1 2023)
- Net corporate free cash flow up 12.7% compared to H1 2023
- Legal challenge to the new French long-distance transportation infrastructure tax (TEILD) ongoing
- APRR and Eiffage consortium awarded A412 motorway project
- Hugh Wehby appointed as incoming CEO and Managing Director commencing late 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Appendix 4D and Interim Financial Report
|
29 Aug 2024 8:15AM |
$5.090 |
$5.100 |
risen by
0.20%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Interim Financial Reports prepared in accordance with Australian Accounting Standards and IAS 34
- Atlas Arteria (ALX) comprises Atlas Arteria International Limited (ATLIX) and Atlas Arteria Limited (ATLAX)
- Net profit after tax attributable to Atlas Arteria stapled securityholders decreased by 16.3% to A$114.2 million
- Revenue and other income increased by 9.6% to A$69.6 million
- Dividends of 20.0 cents per stapled security declared
- Net tangible asset backing per stapled security decreased to A$2.76 from A$2.99
- ALX owns interests in toll roads in France, the US, and Germany
- Toll revenue increased despite decreased traffic numbers due to farmers' strikes in France
- Strategic updates include refinancing debt facilities and releasing trapped cash within the APRR Group
- EBITDA on a proportional basis was €337.7 million for APRR Group in H1 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Hugh Wehby Appointed as CEO and Managing Director
|
21 Aug 2024 8:09AM |
$5.080 |
$5.100 |
risen by
0.39%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlas Arteria announced the appointment of Hugh Wehby as the new CEO and Managing Director.
- Hugh Wehby has extensive experience in the Australian listed infrastructure market, having held executive roles at Transurban and Sydney Airport.
- Wehby will focus on driving operational excellence, pursuing growth opportunities, and managing the company’s balance sheet.
- He has a track record of resolving complex issues and driving strategic investment partnerships.
- Wehby’s compensation includes a buy-out of deferred incentives from his former employer.
- His employment terms include a fixed remuneration, travel allowance, and participation in short term and long term incentive plans.
- Wehby expressed his commitment to safety, sustainability, and people, and looks forward to expanding efforts in these areas at Atlas Arteria.
- Atlas Arteria has undergone significant transformation since 2018, including enlarging its portfolio and strengthening its business capital structures.
- The company holds interests in multiple toll roads, including APRR in France, Chicago Skyway in the US, and Warnow Tunnel in Germany.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Appendix 3X - Danny Elia
|
6 Aug 2024 3:15PM |
$5.080 |
$5.100 |
risen by
0.39%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Danny Elia Appointment and Agreement on Governance
|
6 Aug 2024 9:21AM |
$5.050 |
$5.100 |
risen by
0.99%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Ceasing to be a substantial holder
|
6 Aug 2024 8:17AM |
$5.050 |
$5.100 |
risen by
0.99%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Becoming a substantial holder
|
1 Aug 2024 8:23AM |
$5.240 |
$5.100 |
fallen by
2.67%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Notice of H1 2024 Results Presentation
|
31 Jul 2024 9:04AM |
$5.140 |
$5.100 |
fallen by
0.78%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Ceasing to be a substantial holder
|
31 Jul 2024 8:11AM |
$5.140 |
$5.100 |
fallen by
0.78%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Becoming a substantial holder
|
30 Jul 2024 8:24AM |
$5.180 |
$5.100 |
fallen by
1.54%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Ceasing to be a substantial holder
|
26 Jul 2024 8:21AM |
$5.130 |
$5.100 |
fallen by
0.58%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Becoming a substantial holder
|
25 Jul 2024 8:25AM |
$5.170 |
$5.100 |
fallen by
1.35%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Q2 2024 Revenue and Traffic Update
|
23 Jul 2024 8:32AM |
$5.140 |
$5.100 |
fallen by
0.78%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Weighted average traffic decreased by 0.2% in Q2 2024.
- Weighted average toll revenue increased by 4.6% in Q2 2024.
- APRR traffic fell 1.0%, but toll revenue increased by 3.8%.
- Chicago Skyway traffic grew by 0.9%, with a 9.6% rise in revenue.
- Dulles Greenway traffic rose by 5.4%, accompanied by a 6.3% increase in revenue.
- A79 traffic increased by 7.3%, and toll revenue grew by 12.9%.
- Warnow Tunnel traffic was up by 1.1%, with a 9.8% increase in revenue.
- Traffic results were influenced by factors such as roadworks and the timing of holidays.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Completion of Chicago Skyway Refinancing
|
11 Jul 2024 9:10AM |
$5.110 |
$5.100 |
fallen by
0.20%
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Ceasing to be a substantial holder
|
8 Jul 2024 8:19AM |
n/a |
$5.100 |
n/a
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
New ATLIX Bye-Laws
|
3 Jul 2024 4:33PM |
n/a |
$5.100 |
n/a
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
Becoming a substantial holder
|
3 Jul 2024 8:24AM |
n/a |
$5.100 |
n/a
|
|
| Atlas Arteria (ALX) FPO STAP US PROHIBITED EXCLUDING QIB/QP |
Industrials |
$7,401 |
APRR Capital Management Initiatives
|
1 Jul 2024 8:35AM |
$5.110 |
$5.100 |
fallen by
0.20%
|
|
ALX - Price-sensitive ASX Announcement
Full Release
Key Points
- Agreement to refinance the Financière Eiffarie (FE) debt facility in H1 2025, targeting a materially reduced amortisation profile.
- Release of approximately €200 million of cash within the APRR Group in H2 2024 to fund FE debt amortisation payments.
- Injection of €55.5 million into MAF2 by Eiffage in H2 2024, increasing Eiffage’s economic interest in APRR from 52.0% to 52.5%.
- Atlas Arteria's economic interest in APRR Group will be diluted slightly by 0.32%, to 30.82%.
- The initiatives aim to release trapped profits and cash in the APRR group structure, fund growth, and return excess cash to shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.